1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Global Market Study on Sickle Cell Disease Treatment: Sickle Cell Anaemia Anticipated to be the Most Lucrative Disease Type Segment Through 2025

Global Market Study on Sickle Cell Disease Treatment: Sickle Cell Anaemia Anticipated to be the Most Lucrative Disease Type Segment Through 2025

  • September 2017
  • 224 pages
  • ID: 5138792
  • Format: PDF
  • By Persistence Market Research


Table of Contents

Persistence Market Research has come up with a new report titled “Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),” for the projected period of 8-years.

According to this report, weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. We have not only captured the country price with the local currency but also the local currency figures is converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of country. Prices considered in the models are standardized based on the average dosage used per Sickle cell disease treatment per dosage in a year. Availability of branded off-patent equivalents have been taken into consideration while calculating prices.

We have used following parameters to estimate the global market size
Market sizing is done using our in-house epidemiology data based model to estimate sickle cell disease treatment market. We adopt bottom-up approach to forecast sickle cell disease treatment market globally. The following parameters are used to estimate the market size for the base year 2016:
- Country level data for prevalence and incidence rate for calculating base population
- Diagnosis rate
- Treatment rate and percentage adoption of currently available treatment options in various stages of the disease for calculating target population
- Average cost of drug treatment cycle associated with the each treatment option
- Average cost of each cycle is then multiplied by average number of cycles taken by patients for all drug type (differs from drug to drug) in an year
- We have used a number of sources to present a detailed analysis of the global sickle cell disease treatment market

Our research methodology uses both primary and secondary research to collect the relevant data. We have analyzed the market by considering the revenue through extensive primary research to understand the usage pattern, historic trends, and problems faced by the physicians, the required treatment developments, and most preferred drugs. Key opinion leaders were considered for the primary research that included experienced healthcare professionals in various healthcare facilities at country level. These estimates were further validated with drug manufacturers, distributors, and suppliers.

Extensive secondary research has been carried out to understand the epidemiology of sickle cell disease, treatment rate, adoption rate, regulatory scenarios, average selling price, reimbursement scenario, by referring published scientific literature from various databases such as the WHO, National Heart, Lung, and Blood Institute (NHLBI), PubMed, Springer, and Wiley among many others. We have also analyzed various companies’ annual report, investor presentation, SEC filings, 10k reports and press release operating in sickle cell disease treatment market to fetch substantial information about the market size, trends, opportunity, drivers, and restraints to analyze key players.

Report Inclusions and Exclusions
In this report, we have considered only those drugs that are administered for sickle cell disease treatment. The study includes drugs such as hydroxyurea, antibiotics, pain-relieving medications and others. The drugs considered in others segments are drugs that are administered based on patients conditions and also includes the newly FDA approved drug L-Glutamine for sickle cell disease treatment.

We have not included other therapies such as surgeries, blood transfusions, gene therapies and bone marrow transplantation etc. to calculate market value in this study. The market also do not includes any products from the drug type segment administered to patients of any other indications. The market value is calculated based on only the drug type (Hydroxyurea, Antibiotics, Pain-relieving medications, and other drugs) administered for sickle cell disease treatment.

Forecast Assumptions and Limitations

To forecast the market we have considered the following assumptions:
Growth in diagnosis and treatment rate
Change in price of drugs
Adoption curve for available treatment
Impact of launch of new combination regimen which are in late stage of development
Forecasting has been done on a static base and only currently approved products have been taken into consideration for calculating the actual size of the treatment market
Our clients should note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting is done on our internal proprietary model which also uses different macro-economic factors and industry based demand driving factors that are impacting the market and its forecast trends apart from disease related factors.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on